ING Groep NV Invests $1.03 Million in HCA Healthcare, Inc. $HCA

ING Groep NV bought a new position in shares of HCA Healthcare, Inc. (NYSE:HCA) during the third quarter, HoldingsChannel.com reports. The firm bought 2,405 shares of the company’s stock, valued at approximately $1,025,000.

Several other institutional investors and hedge funds have also made changes to their positions in HCA. Clearstead Trust LLC increased its holdings in HCA Healthcare by 311.8% during the 2nd quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock valued at $27,000 after acquiring an additional 53 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in shares of HCA Healthcare by 82.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock worth $32,000 after purchasing an additional 34 shares in the last quarter. Twin Peaks Wealth Advisors LLC acquired a new stake in HCA Healthcare during the 2nd quarter valued at $40,000. Compound Global Advisors LLC acquired a new position in shares of HCA Healthcare in the third quarter worth $44,000. Finally, True Wealth Design LLC boosted its stake in shares of HCA Healthcare by 179.5% during the third quarter. True Wealth Design LLC now owns 109 shares of the company’s stock valued at $47,000 after acquiring an additional 70 shares during the last quarter. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

HCA Healthcare Price Performance

Shares of NYSE:HCA opened at $539.91 on Friday. The firm has a market capitalization of $120.73 billion, a PE ratio of 19.02, a P/E/G ratio of 1.66 and a beta of 1.36. HCA Healthcare, Inc. has a 12 month low of $295.00 and a 12 month high of $552.90. The business has a 50-day moving average of $482.80 and a two-hundred day moving average of $448.96.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Tuesday, January 27th. The company reported $8.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.37 by $0.64. The firm had revenue of $19.51 billion during the quarter, compared to the consensus estimate of $19.67 billion. HCA Healthcare had a net margin of 8.97% and a negative return on equity of 409.11%. The company’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.22 EPS. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, research analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 17th will be given a dividend of $0.78 per share. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.72. The ex-dividend date of this dividend is Tuesday, March 17th. This represents a $3.12 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s dividend payout ratio is currently 10.15%.

Insider Buying and Selling at HCA Healthcare

In other HCA Healthcare news, SVP Christopher F. Wyatt sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $505.00, for a total value of $2,020,000.00. Following the completion of the transaction, the senior vice president owned 44,379 shares in the company, valued at $22,411,395. This represents a 8.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael S. Cuffe sold 1,500 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total transaction of $747,135.00. Following the completion of the transaction, the executive vice president owned 30,003 shares of the company’s stock, valued at $14,944,194.27. This trade represents a 4.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 13,520 shares of company stock valued at $6,894,067 over the last three months. 1.30% of the stock is owned by company insiders.

Key HCA Healthcare News

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA’s share performance is strong on a year‑over‑year basis (shares up ~75% YoY), reinforcing momentum and investor confidence in the company’s results and outlook. Read More.
• Positive Sentiment: Zacks and other analysts highlight earnings growth and price strength; Zacks added HCA to focus coverage and raised FY‑2026 EPS estimates, supporting forward earnings momentum and valuation. Read More.
• Positive Sentiment: HCA raised its quarterly dividend (new quarterly payout announced), which narrows yield risk and is a modest positive for income‑oriented investors. Read More.
• Positive Sentiment: Large institutional flows and stake increases (e.g., Norges Bank, Pacer, Viking Global) point to strong institutional demand and provide technical/supportive buying pressure for the stock. Read More.
• Neutral Sentiment: HCA completed a 43‑hospital EHR rollout and is tracking success metrics — operational execution that can improve efficiency and integration over time but has a gradual, not immediate, earnings impact. Read More.
• Neutral Sentiment: Local expansion moves — HCA Houston Healthcare Tomball acquired Supreme Care ER and StoneSprings plans a freestanding ER conversion — small, market‑level capacity adds that could modestly lift volumes in those geographies. Read More.
• Neutral Sentiment: HCA sold ASC real estate — a financing/portfolio move that could free capital or change lease terms; impact depends on transaction use of proceeds. Read More.
• Negative Sentiment: Insider selling: two senior VPs disclosed multi‑million dollar sales (Christopher Wyatt sold ~$2.0M; Jennifer Berres sold ~$4.13M). Significant insider sales can create short‑term selling pressure or raise governance/portfolio‑rebalancing questions. Read More. Read More.
• Negative Sentiment: Zacks/other outlets flagged a downward revision to HCA’s Q1 EPS forecast, which can pressure near‑term expectations even as FY estimates were raised. Read More.

Wall Street Analysts Forecast Growth

HCA has been the topic of several analyst reports. UBS Group raised their price target on shares of HCA Healthcare from $525.00 to $598.00 and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Cantor Fitzgerald lifted their target price on shares of HCA Healthcare from $525.00 to $588.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 28th. Weiss Ratings restated a “buy (b)” rating on shares of HCA Healthcare in a report on Monday, December 29th. Wells Fargo & Company increased their target price on HCA Healthcare from $452.00 to $481.00 and gave the stock an “equal weight” rating in a research report on Friday, January 30th. Finally, Argus upped their price objective on shares of HCA Healthcare from $530.00 to $560.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Sixteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, HCA Healthcare currently has an average rating of “Moderate Buy” and an average target price of $523.27.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.